MESOBLAST LIMITED

2.97%

$1.80

Market Cap $2.293B

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) accelerates commercialisation with positive Phase II results.

Latest Threads

Tag

Subject

MSB

Ann: Mesoblast Maintains Momentum with FDA

2 3

14/06/25

126

42K

14/06/25

Last post stockrock

126

42K

MSB

Cell Therapy News/Articles

326 327 328

14/06/25

19K

8.1M

14/06/25

Last post stocksa

19K

8.1M

MSB

banter and General Discussion

291 292 293

14/06/25

17K

6.2M

14/06/25

Last post Wilba32

17K

6.2M

MSB Biotech

MSB - a new dawn

32 33 34

14/06/25

1.9K

822K

14/06/25

Last post exec925

1.9K

822K

MSB

MESO Nasdaq update

113 114 115

14/06/25

6.8K

3.5M

14/06/25

Last post rakeshnirzari1

6.8K

3.5M

MSB

NASDAQ Meso daily flow charts

2 3 4

14/06/25

209

83K

14/06/25

Last post Wilba32

209

83K

MSB

Chart

5 6 7

14/06/25

369

160K

14/06/25

Last post Medicalcentral

369

160K

MSB

Mesoblast 2025: The year of acting like a publicly listed company

19 20 21

13/06/25

1.2K

452K

13/06/25

Last post Pledge

1.2K

452K

See All Discussions

Timeline

Mesoblast Maintains Momentum with FDA
12 Jun 10:14	Share

Becoming a substantial holder
06 Jun 08:21	Share

Becoming a substantial holder
05 Jun 08:18	Share

Becoming a substantial holder
03 Jun 15:59	Share

Ceasing to be a substantial holder
03 Jun 08:21	Share

FDA Provides Ryoncil 7 Years Orphan-Drug Exclusive Approval
15 May 10:01	Share

Becoming a substantial holder
14 May 08:18	Share

Ceasing to be a substantial holder
09 May 08:24	Share

Becoming a substantial holder
08 May 08:20	Share

Ceasing to be a substantial holder
07 May 15:26	Share

Becoming a substantial holder
02 May 14:07	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 10:13	Share

Initial Director's Interest Notice
29 Apr 09:37	Share

Director Appointment
29 Apr 09:19	Share

Appendix 3Y for Gregory George
24 Apr 09:26	Share

Mesoblast Extends Ryoncil Payer Coverage To 104M US Lives
17 Apr 10:07	Share

Notification of cessation of securities - MSB
14 Apr 18:42	Share

Notification regarding unquoted securities - MSB
14 Apr 18:38	Share

Application for quotation of securities - MSB
14 Apr 18:31	Share

Notification regarding unquoted securities - MSB
14 Apr 18:30	Share

Appendix 3Y - Silviu Itescu, Eric Rose and Philip Krause
08 Apr 19:09	Share

Notification regarding unquoted securities - MSB
08 Apr 18:56	Share

Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs
04 Apr 09:33	Share

Meeting Requested with FDA on Revascor Accelerated Approval
03 Apr 09:51	Share

First Children To Begin Treatment, Medicaid Covers Ryoncil
31 Mar 09:59	Share

Ryoncil Is Now Available For Purchase In The United States
27 Mar 10:12	Share

Ryoncil Published in All Four Major Drug Pricing Compendia
14 Mar 09:57	Share

CEO Presentation at ISCT North America
13 Mar 09:54	Share

Appendix 3Y for Gregory George
13 Mar 09:50	Share

CEO to Deliver Featured Presentation at ISCT North America
12 Mar 18:24	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.80		Change -0.055(2.97%)		Mkt cap ! $2.293B

Open	High	Low	Value	Volume
$1.84	$1.86	$1.77	$7.241M	4.018M

Buyers (Bids)

No.	Vol.	Price($)
3	25472	$1.80

Sellers (Offers)

Price($)	Vol.	No.
$1.81	1500	1

View Market Depth

No.	Vol.	Price($)
1	485	1.780
4	100773	1.770
2	25500	1.765
3	23000	1.760
7	44464	1.750

Price($)	Vol.	No.
1.805	1500	1
1.810	9500	1
1.820	4000	1
1.835	10000	1
1.840	5000	1

Last trade - 16.10pm 13/06/2025 (20 minute delay)

MSB (ASX) Chart

MESOBLAST LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

Mesoblast (ASX:MSB) flags strengthened heart function in latest trial results

28 Feb 2023 10:07 (AEDT)

Latest Articles

The market shrugged at Mesoblast's latest FDA win. Is it just another Droneshield?

Mesoblast (ASX:MSB) has revealed the US FDA has given its flagship drug a 7 year exclusivity period, blocking...

Mesoblast dips on 'belief' it's not subject to US tariffs – despite Singaporean lab

Mesoblast (ASX:MSB) has seen shares fall just shy of -3% heading into lunchtime trades despite apparent tariff relief.

Mesoblast kicks off treatment for first 3 kids with graft-host disease. So why are shares down?

otCopper favourite Mesoblast (ASX:MSB) has announced it's begun treating the first 3 children with skin graft-versus-host disease in the US, at the same time the company received medicare (US) and medicaid coverage.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News